Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic Analysis ASFRA:8V8 +1.83%34 3-Year ROIIC % is 3,820.17 as of Dec. 2025, which is 1537% above its 10-year median of 233.31. GuruFocus rates FRA:8V8 with a GF Score™ of 34/100 and a GF Value™ of €0.04. The stock has 3 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Genetic Analysis AS ranks better than 97.54% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Genetic Analysis AS's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 3,820.17%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Genetic Analysis AS's 3-Year ROIIC % or its related term are showing as below:
FRA:8V8's 3-Year ROIIC % is ranked better than 97.54% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22
vs FRA:8V8: 3820.17
Genetic Analysis AS (FRA:8V8) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Genetic Analysis AS 3-Year ROIIC % Related Terms
Genetic Analysis AS 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Genetic Analysis AS's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8V8 vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Genetic Analysis AS's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Analysis AS 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Genetic Analysis AS's 3-Year ROIIC % falls into.
Genetic Analysis AS's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.877 (Dec. 2025) - -2.693 (Dec. 2022) )
/
( 3.194 (Dec. 2025) - 3.566 (Dec. 2022) )
=
1.816
/
-0.372
=
-488.17%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Genetic Analysis AS (FRA:8V8) has a 3-Year ROIIC % of 3,820.17 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Genetic Analysis AS and its competitors. This is 1537% above median its historical median of 233.31. According to the industry distribution chart, Genetic Analysis AS ranks #5 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 2.5%.
Is Genetic Analysis AS's 3-Year ROIIC % too high?
Genetic Analysis AS's current 3-Year ROIIC % of 3,820.17 is 1537% above median its 10-year median of 233.31. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.22. Genetic Analysis AS's value of 3,820.17 is 1736340.9% above this industry median. Based on the distribution chart, Genetic Analysis AS ranks #5 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Genetic Analysis AS has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Analysis AS ranks #5 out of 203 companies for 3-Year ROIIC %. This places Genetic Analysis AS in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.22. Genetic Analysis AS's value of 3,820.17 is 1736340.9% above this benchmark. While the company's 10-year median is 233.31 vs. the industry median of 0.22, Genetic Analysis AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.22, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Analysis AS's current 3-Year ROIIC % of 3,820.17 is 1736340.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Genetic Analysis AS and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Analysis AS's current 3-Year ROIIC % is 3,820.17, which is 1537% above median its own 10-year median of 233.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Genetic Analysis AS (FRA:8V8) has a current 3-Year ROIIC % of 3,820.17. The stock's GF Value™ is €0.04, compared to a current price of €0.04 — trading 11.5% above its estimated fair value. The current 3-Year ROIIC % is 3,820.17, which is 1537% above median its 10-year median of 233.31 and 1736340.9% above the Medical Diagnostics & Research industry median of 0.22. Genetic Analysis AS's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Genetic Analysis AS (FRA:8V8), the current 3-Year ROIIC % is 3,820.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetic Analysis AS (FRA:8V8) Overvalued in 2026?
Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued.
The current stock price of €0.04 is trading 11.5% above its estimated GF Value™ of €0.04.
Key valuation signals for FRA:8V8:
3-Year ROIIC %: 3,820.17 (1537% above median its 10-year median of 233.31)
GF Value™: €0.04 vs. price of €0.04 (11.5% above fair value)
Industry Position: 1736340.9% above the Medical Diagnostics & Research median (#5 of 203)
No single metric tells the full story. See the FRA:8V8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
34GF Score
Get the complete analysis for FRA:8V8
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8V8 has been successfully added to your 
